3 results
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
The primary endpoint (equal or improved MSQoL-54 and Eq5d) at which the value of telemonitoring is determined is t = 2 years.Mapping the effects of digital consultations or hospital visits, for MS patients, informal carers and the Isala…
This Phase Ia/Ib study will evaluate the safety, pharmacokinetics, immunogenicity (as applicable for study biotherapeutics), preliminary activity, and biomarkers of GDC-6036 as a single agent (Arm A) and in combination with other anti-cancer…